Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Bought by TD Asset Management Inc

TD Asset Management Inc grew its stake in shares of Wave Life Sciences Ltd. (NASDAQ:WVEFree Report) by 26.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 205,746 shares of the company’s stock after acquiring an additional 43,054 shares during the period. TD Asset Management Inc owned about 0.21% of Wave Life Sciences worth $1,039,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of WVE. Jump Financial LLC purchased a new position in Wave Life Sciences in the 3rd quarter worth about $135,000. Newtyn Management LLC increased its position in shares of Wave Life Sciences by 2.0% in the third quarter. Newtyn Management LLC now owns 510,000 shares of the company’s stock worth $2,932,000 after acquiring an additional 10,000 shares in the last quarter. Laurion Capital Management LP raised its holdings in shares of Wave Life Sciences by 5.1% during the third quarter. Laurion Capital Management LP now owns 871,500 shares of the company’s stock valued at $5,011,000 after acquiring an additional 42,662 shares during the period. Wellington Management Group LLP lifted its position in shares of Wave Life Sciences by 4.3% in the 3rd quarter. Wellington Management Group LLP now owns 264,885 shares of the company’s stock valued at $1,523,000 after acquiring an additional 10,830 shares in the last quarter. Finally, Kraematon Investment Advisors Inc. purchased a new stake in shares of Wave Life Sciences in the 4th quarter valued at approximately $237,000. 89.73% of the stock is owned by institutional investors and hedge funds.

Wave Life Sciences Stock Performance

Shares of WVE opened at $5.81 on Monday. The firm has a market cap of $711.49 million, a PE ratio of -11.17 and a beta of -1.03. The firm’s 50 day moving average price is $5.76 and its 200 day moving average price is $5.29. Wave Life Sciences Ltd. has a twelve month low of $3.45 and a twelve month high of $7.67.

Wave Life Sciences (NASDAQ:WVEGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06). The firm had revenue of $12.54 million for the quarter, compared to analyst estimates of $25.67 million. During the same quarter in the prior year, the company earned ($0.27) EPS. On average, sell-side analysts anticipate that Wave Life Sciences Ltd. will post -0.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on WVE shares. Royal Bank of Canada reissued a “sector perform” rating and set a $5.00 target price on shares of Wave Life Sciences in a research note on Thursday, March 7th. Truist Financial reissued a “buy” rating and issued a $17.00 price objective on shares of Wave Life Sciences in a research note on Monday, April 1st. HC Wainwright lifted their target price on Wave Life Sciences from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, March 7th. Wells Fargo & Company initiated coverage on shares of Wave Life Sciences in a research report on Wednesday, May 15th. They issued an “overweight” rating and a $11.00 price target for the company. Finally, StockNews.com downgraded shares of Wave Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Wave Life Sciences has an average rating of “Moderate Buy” and an average target price of $11.17.

Check Out Our Latest Research Report on Wave Life Sciences

Insiders Place Their Bets

In other news, CFO Kyle Moran sold 15,630 shares of the stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $6.17, for a total transaction of $96,437.10. Following the transaction, the chief financial officer now owns 33,921 shares of the company’s stock, valued at approximately $209,292.57. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 31.10% of the company’s stock.

Wave Life Sciences Company Profile

(Free Report)

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

Featured Stories

Institutional Ownership by Quarter for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.